BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. (Q44542640)
Jump to navigation
Jump to search
scientific article published on 11 September 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. |
scientific article published on 11 September 2012 |
Statements
1 reference
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. (English)
1 reference
Stuart A Rushworth
1 reference
Kristian M Bowles
1 reference
Lawrence N Barrera
1 reference
Megan Y Murray
1 reference
Lyubov Zaitseva
1 reference
David J MacEwan
1 reference
11 September 2012
1 reference
1 reference
Identifiers
1 reference